NOTICE OF MEETING AND AGENDA

Enforcement Committee and E-Pedigree Public Meeting
June 12, 2012

Contact Person: Virginia Herold
(916) 574-7911

This board meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Richard Hultgren at (916) 574-7934, by emailing richard.hultgren@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

DATE: June 12, 2012
PLACE: The Westgate Hotel
1055 Second Avenue
San Diego, CA 92101

WEBCAST: http://www.pharmacy.ca.gov/meetings/current_webcasts.shtml
(link to Webcast will not be available until 9:30 a.m. on June 12, 2012)

Agenda items may be taken out of order to accommodate speakers and to maintain a quorum. The meeting may be cancelled without notice. For verification of the meeting, call (916) 574-7900 or access the Board’s Web site at www.pharmacy.ca.gov.

Discussion and action may be taken on any item on the agenda. An opportunity for public comment is provided for each open agenda item and at the end of each committee’s report. All times are approximate and subject to change. Time limitations for discussion and comment will be determined by the President.

Agenda

Tuesday, June 12, 2012

Call to Order 9:30 a.m.

I. Presentation and Discussion on the Use of the Pharmacist Assessment for Remediation Evaluation (PARE) Examination in California as an Optional Enforcement Tool to Assess Pharmacist Practice Deficiencies

Meeting Materials will be available on the board’s Web site at www.pharmacy.ca.gov by June 8, 2012.
II. Discussion on the Implementation of California’s Electronic Pedigree Requirements for Prescription Medication
   a. Discussion about the Presence of Counterfeit Avastin and Altuzan in California Physician Offices and Clinics
   b. Dysfunction In California’s Supply of Prescription Medication Discovered During Board of Pharmacy Investigations
   c. Board of Pharmacy’s Letters to Federal Representatives and Senators on Elements Needed in any Proposal for Federal Legislation
   d. Colloquy from Senators Enzi and Harkin in Support of Retaining Protections in California Law in Future Federal Requirements for Tracking Prescription Medications Through Pharmaceutical Supply Chain
   e. Presentations and Questions from the Pharmaceutical Supply Chain on Their Readiness to Meet California’s Staggered E-Pedigree Implementation Schedule
      1. Robert Celeste, Director, Healthcare, GS1 US
      2. Other Companies, Associations and Other Entities Wishing to Address the Committee on E-Pedigree Issues
   f. General Discussion
   g. Discussion and Possible Action to Develop Regulation Requirements Specifying a Unique Identification Number for Prescription Medication Pursuant to California’s E-Pedigree Requirements
   h. Discussion and Possible Action to Develop “Grandfathering” Provisions for Non-Pedigreed Dangerous Drugs Pursuant to Section 4163.2 of the Business and Professions Code
   i. Discussion concerning Elements for Inference as Provided by California Business and Professions Code Section 4163.3
   j. Closing Comments

III. Public Comment on Items Not on the Agenda/Agenda Items For Future Meetings
   Note: The committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code Sections 11125, 11125.7(a)]

ADJOURNMENT 4 p.m.